7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection-Reference-Cited by-同舟云学术

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

Published:2023-02 Issue:2 Volume:23 Page:150-152
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Marking Ulrika,Bladh Oscar,Havervall Sebastian,Svensson Julia,Greilert-Norin Nina,Aguilera Katherina,Kihlgren Martha,Salomonsson Ann-Cristin,Månsson Maja,Gallini Radiosa,Kriegholm Cecilia,Bacchus Philip,Hober Sophia,Gordon Max,Blom Kim,Smed-Sörensen Anna,Åberg Mikael,Klingström Jonas,Thålin Charlotte

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference7 articles.

1. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence;Focosi;Viruses,2022

2. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection;Havervall;N Engl J Med,2022

3. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection;Gilboa;JAMA Netw Open,2022

4. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection;Blom;Lancet Infect Dis,2022

5. Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure;Reynolds;Science,2022

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands;Mucosal Immunology;2024-08

2. Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters;Nature Communications;2024-07-23

3. Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies;Signal Transduction and Targeted Therapy;2024-07-22

4. Serum anti-nucleocapsid antibody level induced after primary infection is an immunological surrogate of protection against SARS-CoV-2 re-infection in hybrid immunity holders;2024-06-06

5. SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response;Influenza and Other Respiratory Viruses;2024-06